XML 32 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
License and Collaboration Agreements - Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total $ 16,440,000 $ 28,002,000 $ 67,839,000 $ 68,851,000  
Baxalta [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total   0   0  
Sanofi [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total     0    
License and Collaboration Agreements [Member] | Baxalta [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Proportional performance model 16,440,000   47,839,000    
Substantive milestones     20,000,000    
Total 16,440,000   67,839,000    
Accounts receivable, billed 1,125,000   1,125,000    
Accounts receivable, unbilled 840,000   840,000   $ 1,615,000
Deferred revenue $ 65,136,000   $ 65,136,000   91,156,000
License and Collaboration Agreements [Member] | Sanofi [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront payment   13,415,000   27,933,000  
Milestone payments   5,590,000   11,639,000  
Development services   2,953,000   16,694,000  
Manufacturing services and other   6,044,000   12,585,000  
Total   $ 28,002,000   $ 68,851,000  
Accounts receivable, billed         369,000
Accounts receivable, unbilled         $ 1,282,000